Kerins Patrick J's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Dec 27, 2021
- Accession no.
- 0001209191-21-071262
- Filed
- Dec 27, 2021, 4:34 PM ET
- Trade date
- Dec 9-23, 2021
- Filing delay
- 18 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 11 non-derivative transactions. Open-market sales total $688.5K. It was filed 18 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kerins Patrick JCIK 0001235112 | 10% Owner |
| Sandell Scott DCIK 0001237289 | 10% Owner |
| Baskett ForestCIK 0001277631 | 10% Owner |
| New Enterprise Associates 14, L.P.CIK 0001544328 | 10% Owner |
| NEA Partners 14, L.P.CIK 0001551531 | 10% Owner |
| Nea 14 GP, LtdCIK 0001551532 | 10% Owner |
| Sonsini Peter W.CIK 0001559807 | 10% Owner |
| Florence Anthony A. Jr.CIK 0001559827 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2021 | Common Stock | SSaleDisposed | −5,666 | $2.95 | −$16,693.17 | 4,008,329 | Direct | |
| Dec 10, 2021 | Common Stock | SSaleDisposed | −8,667 | $2.83 | −$24,541.48 | 3,999,662 | Direct | |
| Dec 13, 2021 | Common Stock | SSaleDisposed | −17,501 | $2.83 | −$49,557.58 | 3,982,161 | Direct | |
| Dec 14, 2021 | Common Stock | SSaleDisposed | −15,093 | $2.56 | −$38,642.61 | 3,967,068 | Direct | |
| Dec 15, 2021 | Common Stock | SSaleDisposed | −28,817 | $2.28 | −$65,685.47 | 3,938,251 | Direct | |
| Dec 16, 2021 | Common Stock | SSaleDisposed | −44,993 | $2.23 | −$100,545.86 | 3,893,258 | Direct | |
| Dec 20, 2021 | Common Stock | SSaleDisposed | −47,000 | $2.21 | −$103,884.1 | 3,846,258 | Direct | |
| Dec 20, 2021 | Common Stock | SSaleDisposed | −38,123 | $2.33 | −$88,719.85 | 3,808,135 | Direct | |
| Dec 21, 2021 | Common Stock | SSaleDisposed | −41,222 | $2.32 | −$95,804.05 | 3,766,913 | Direct | |
| Dec 22, 2021 | Common Stock | SSaleDisposed | −20,109 | $2.32 | −$46,679.02 | 3,746,804 | Direct | |
| Dec 23, 2021 | Common Stock | SSaleDisposed | −23,961 | $2.41 | −$57,746.01 | 3,722,843 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.